Incyte Corp.INCY
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · incyte.com
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for oncology, inflammation, and autoimmune diseases. Its key marketed product, Jakafi (ruxolitinib), is approved for myelofibrosis, polycythemia vera, and acute graft-versus-host disease, and the company also has a growing portfolio of dermatology and oncology treatments.
Key ratios
Operating cash flow growth
97.4%TTM
2025
321.5%2024
-32.5%2023
-48.8%
EPS growth
79.7%TTM
2025
4173.3%2024
-94.3%2023
74.3%
FCF / Sales
26.3%TTM
2025
26.3%2024
5.9%2023
12.6%
Net margin
27.7%TTM
2025
25.0%2024
0.8%2023
16.2%
ROA
13.6%TTM
2025
13.6%2024
0.9%2023
6.5%
ROE
30.7%TTM
2025
29.9%2024
0.8%2023
12.5%
Revenue growth
21.2%2025
2024
14.8%2023
8.9%
Recent news
Incyte Announces Funding of MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Incyte gains $246M non-cash boost from CMS deal
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Track INCY in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer